Design of rhinovirus protease inhibitors for the treatment of the common cold

Drugs of the Future

Volumn 25, Issue 3, 2000, Pages 279-286

  Wang, Q May ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ISATIN DERIVATIVE; PHTHALIMIDE DERIVATIVE; PROTEINASE INHIBITOR; RUPINTRIVIR; UNCLASSIFIED DRUG;

COMMON COLD; DRUG DESIGN; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG STRUCTURE; DRUG TARGETING; DRUG TOLERABILITY; NONHUMAN; REVIEW; RHINOVIRUS;

EID: 0034091629     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2000.025.03.858657     Document Type: Review

References (86)

1. Roeckert, R.R. Picornaviridae: The viruses and their replication. In: Fields Virology. Fields, B.N. et al. (Eds.). Raven Publishers: Philadelphia 1996, 609-54.
2. Melnick, J.L. Enteroviruses: Polioviruses, coxsackieviruses, echoviruses, and newer enteroviruses. In: Fields Virology. Fields, B.N. et al. (Eds.). Raven Publishers: Philadelphia 1996, 655-712.
3. Couch, R.B. Rhinoviruses. In: Fields Virology. Fields, B.N. et al. (Eds.). Raven Publishers: Philadelphia 1996, 713-34.
4. Hollinger, F.B., Ticehurst, J.R. Hepatitis A virus. In: Fields Virology. Fields, B.N. et al. (Eds.). Raven Publishers: Philadelphia 1996, 735-82.
5. Andries, K., Dewindt, B., Snoeks, J., Willebrords, R., Stokbroekx, R., Lewi, P.J. A comparative test of fifteen compounds against all known human rhinovirus serotypes as a basis for a more rational screening program. Antiviral Res 1991, 16: 213-25.
6. Rossmann, M.G. Viral cell recognition and entry. Protein Sci 1994, 3: 1712-25.
7. Porter, A.G. Picornavirus nonstructural proteins: Emerging roles in virus replication and inhibition of host cell functions. J Virol 1993, 67: 6917-21.
8. Palmenberg, A.C. Proteolytic procession of picornaviral polyprotein. Annu Rev Microbiol 1990, 44: 603-23.
9. Stanway, G. Structure, function, and evolution of picornaviruses. J Gen Virol 1990, 71: 2483-501.
10. Hellen, C.U.T., Wimmer, E. Maturation of poliovirus capsid proteins. Virology 1992, 187: 391-7.
11. Toyoda, H., Nicklin, M.J., Murray, M.G. et al. A second virus-encoded proteinase involved in proteolytic processing of poliovirus polyprotein. Cell 1986, 45: 761-70.
12. Krausslich, H.G., Nicklin, M.J., Lee, C.K., Wimmer, E. Polyprotein processing in picornavirus replication. Biochimie 1988, 70: 119-30.
13. Nicklin, M.J., Krausslich, H.G., Toyoda, H., Dunn, J.J., Wimmer, E. Poliovirus polypeptide precursors: Expression in vitro and processing by exogenous 3C and 2A proteinases. Proc Natl Acad Sci USA 1987, 84: 4002-6.
14. Sommergruber, W., Zorn, M., Blaas, D. et al. Polypeptide 2A of human rhinovirus type 2: Identification as a protease and characterization by mutational analysis. Virology 1989, 169: 68-77.
15. Krausslich, H.G., Nicklin, M.J., Toyoda, H., Etchison, D., Wimmer, E. Poliovirus proteinase 2A induces cleavage of eukaryotic initiation factor 4F polypeptide p220. J Virol 1987, 61: 2711-8.
16. Lloyd, R.E., Grubman, M.J., Ehrenfeld, E. Relationship of p220 cleavage during picornavirus infection to 2A proteinase sequencing. J Virol 1988, 62: 4216-23.
17. Hellen, C.U.T., Fäcke, M., Kräusslich, H.G., Lee, C.K., Wimmer, E. Characterization of poliovirus 2A proteinase by mutational analysis: Residues required for autocatalytic activity are essential for induction of cleavage of eukaryotic initiation factor 4F polypeptide p220. J Virol 1991, 65: 4226-31.
18. Liebig, H.D., Ziegler, E., Van, R. et al. Purification of two picornaviral 2A proteinases: Interaction with elF-4γ and influence on in vitro translation. Biochemistry 1993, 32: 7581-8.
19. Sommergruber, W., Ahorn, H., Klump, H. et al. 2A proteinases of coxsackie-and rhinovirus cleave peptides derived from elF-4γ via a common recognition motif. Virology 1994, 198: 741-5.
20. Novoa, I., Martinez-Abarca, F., Fortes, P., Ortin, J., Carrasco, L. Cleavage of p220 by purified poliovirus 2A(pro) in cell-free systems: Effects on translation of capped and uncapped mRNAs. Biochemistry 1997, 36: 7802-9.
21. Davies, M.V., Pelletier, J., Meerovitch, K., Sonenberg, N., Kaufman, R.J. The effect of poliovirus proteinase 2Apro expression on cellular metabolism. Inhibition of DNA replication, RNA polymerase II transcription, and translation. J Biol Chem 1991, 266: 14714-20.
22. Falk, M.M., Grigera, P.R., Bergmann, I.E., Zibert, A., Multhaup, G., Beck, E. Foot and mouth disease virus protease 3C induces specific proteolytic cleavage of host cell histone H3. J Virol 1990, 64: 748-56.
23. Clark, M.E., Hämmerle, T., Wimmer, E., Dasgupta, A. Poliovirus proteinase 3C converts an active form of transcription factor IIIC to an inactive form: A mechanism for inhibition of host cell polymerase III transcription by poliovirus. EMBO J 1991, 10: 2941-7.
24. Clark, M.E., Lieberman, P.M., Berk, A.J., Dasgupta, A. Direct cleavage of human TATA-binding protein by poliovirus protease 3C in vivo and in vitro. Mol Cell Biol 1993, 13: 1232-7.
25. Joachims, M., Harris, K.S., Etchison, D. Poliovirus protease 3C mediates cleavage of microtubule-associated protein 4. Virology 1995, 211: 451-61.
26. Yalamanchili, P., Datta, U., Dasgupta, A. Inhibition of host cell transcription by poliovirus: Cleavage of transcription factor CREB by poliovirus-encoded protease 3Cpro. J Virol 1997, 71: 1220-6.
27. Yalamanchili, P., Weidman, K., Dasgupta, A. Cleavage of transcriptional activator Oct-1 by poliovirus encoded protease 3Cpro. Virology 1997, 239: 176-85.
28. König, H., Rosenwirth, B. Purification and partial characterization of poliovirus protease 2A by means of a functional assay. J Virol 1988, 62: 1243-50.
29. Molla, A., Hellen, C.U.T., Wimmer, E. Inhibition of proteolytic activity of poliovirus and rhinovirus 2A proteinases by elastase-specific inhibitors. J Virol 1993, 67: 4688-95.
30. Bazan, J.F., Fletterick, R.J. Viral cysteine proteases are homologous to the trypsin-like family of serine proteases: Structural and functional implications. Proc Natl Acad Sci USA 1988, 85: 7872-6.
31. Cheah, K.C., Leong, L.E., Porter, A.G. Site-directed mutagenesis suggests close functional relationship between a human rhinovirus 3C cysteine protease and cellular trypsin-like serine proteases. J Biol Chem 1990, 265: 7180-7.
32. Yu, S.F., Llyod, R.E. Identification of essential amino acid residues in the functional activity of poliovirus 2A protease. Virology 1991, 182: 615-25.
33. Sommergruber, W., Seipelt, J., Fessl, F., Skern, T., Liebig, H.D., Casari, G. Mutational analyses support a model for the HRV2 2A proteinase. Virology 1997, 234: 203-14.
34. Matthews, D.A., Smith, W.A., Ferre, R.A. et al. Structure of human rhinovirus 3C protease reveals a trypsin-like polypeptide fold, RNA-binding site, and means for cleaving precursor polyprotein. Cell 1994, 77: 761-71.
35. Gorbalenya, A.E., Blinov, V.M., Donchenko, A.P. Poliovirus-encoded proteinase 3C: A possible evolutionary link between cellular serine and cysteine proteinase families. FEBS Lett 1986, 194: 253-7.
36. Lawson, M.A., Semler, B.L. Poliovirus thiol proteinase 3C can utilize a serine nucleophile within the putative catalytic triad. Proc Natl Acad Sci USA 1991, 88: 9919-23.
37. Allaire, M., Chernaia, M.M., Malcolm, B.A., James, M.N. Picornaviral 3C cysteine proteinases have a fold similar to chymotrypsin-like serine proteinases. Nature 1994, 369: 72-6.
38. Malcolm, B.A. The picornaviral 3C proteinases: Cysteine nucleophiles in serine proteinase folds. Protein Sci 1995, 4: 1439-45.
39. Kean, K.M., Teterina, N.L., Marc, D., Girard, M. Analysis of putative active site residues of the poliovirus 3C protease. Virology 1991, 181: 609-19.
40. Wang, Q.M., Johnson, R.B., Cox, G.A., Villarreal, E.C., Churgay, L.M., Hale, J.E. Enzymatic characterization of refolded human rhinovirus type 14 2A protease expressed in Escherichia coli. J Virol 1998, 72: 1683-7.
41. Libby, R.T., Cosman, D., Cooney, M.K., Merriam, J.E., March, C.J., Hopp, T.P. Human rhinovirus 3C protease: Cloning and expression of an active form in Escherichia coli. Biochemistry 1988, 27: 6262-8.
42. Knott, J.A., Orr, D.C., Montgomery, D.S., Sullivan, C.A., Weston, A. The expression and purification of human rhinovirus protease 3C. Eur J Biochem 1989, 182: 547-55.
43. Aschauer, B., Werner, G., McCray, J., Rosenwirth, B., Bachmayer, H. Biologically active protease 3C of human rhinovirus 1A is expressed from a cloned cDNA segment in Escherichia coli. Virology 1991, 184: 587-94.
44. Birch, G.M., Black, T., Malcolm, S.K., Lai, M.T., Zimmerman, R.E., Jaskunas, S.R. Purification of recombinant human rhinovirus 14 3C protease expressed in Escherichia coli. Protein Expr Purif 1995, 6: 609-18.
45. Davis, G.J., Wang, Q.M., Cox, G.A. et al. Expression and purification of recombinant rhinovirus 14 3CD proteinase and its comparison to the 3C proteinase. Arch Biochem Biophys 1997, 346: 125-30.
46. Skern, T., Sommergruber, W., Auer, H. et al. Substrate requirements of a human rhinoviral 2A proteinase. Virology 1991, 181: 46-54.
47. Sommergruber, W., Ahorn, H., Zöphel, A. et al. Cleavage specificity on synthetic peptide substrates of human rhinovirus 2 proteinase 2A. J Biol Chem 1992, 267: 22639-44.
48. Wang, Q.M., Sommergruber, W., Johnson, R.B. Cleavage specificity of human rhinovirus-2 2A protease for peptide substrates. Biochem Biophys Res Commun 1997, 235: 562-6.
49. Wang, Q.M., Johnson, R.B., Sommergruber, W., Shepherd, T.A. Development of in vitro peptide substrates for human rhinovirus-14 2A protease. Arch Biochem Biophys 1998, 356: 12-8.
50. Cordingley, M.G., Register, R.B., Callahan, P.L., Garsky, V.M., Colonno, R.J. Cleavage of small peptides in vitro by human rhinovirus 14 3C protease expressed in Escherichia coli. J Virol 1989, 63: 5037-45.
51. Orr, D.C., Long, A.C., Kay, J., Dunn, B.M., Cameron, J.M. Hydrolysis of a series of synthetic peptide substrates by the human rhinovirus 14 3C proteinase, cloned and expressed in Escherichia coli. J Gen Virol 1989, 70: 2931-42.
52. Cordingley, M.G., Callahan, P.L., Sardana, V.V., Garsky, V.M., Colonno, R.J. Substrate requirements of human rhinovirus 3C protease for peptide cleavage in vitro. J Biol Chem 1990, 265: 9062-5.
53. Hopkins, J.L., Betageri, R., Cohen, K.A. et al. Rhinovirus 3C protease catalyzes efficient cleavage of a fluorescein-labeled peptide affording a rapid and robust assay. J Biochem Biophys Methods 1991, 23: 107-13.
54. McCall, J.O., Kadam, S., Katz, L. A high capacity microbial screen for inhibitors of human rhinovirus protease 3C. BioTechnology 1994, 12: 1012-6.
55. Wang, Q.M., Johnson, R.B., Cox, G.A., Villarreal, E.C., Loncharich, R.J. A continuous colorimetric assay for rhinovirus-14 3C protease using peptide p-nitroanilides as substrates. Anal Biochem 1997, 252: 238-45.
56. Wang, Q.M., Johnson, R.B., Cohen, J.D., Voy, G.T., Richardson, J.M., Jungheim, L.N. Development of a continuous fluorescence assay for rhinovirus-14 3C protease using synthetic peptides. Antiviral Chem Chemother 1997, 8: 303-10.
57. Saunders, J., Cameron, J.M. Recent developments in the design of antiviral agents. Med Res Rev 1995, 15: 497-531.
58. Mills, J.S. Virus proteinase inhibitors - what next after HIV? Antiviral Chem Chemother 1996, 7: 281-93.
59. Patick, A.K., Potts, K.E. Protease inhibitors as antiviral agents. Clin Microbiol Rev 1998, 11: 614-27.
60. Guiles, J.W. Antipicornaviral compounds and their use as a common cold therapy. Exp Opin Ther Patents 1997, 7: 123-8.
61. Wang, Q.M. Human rhinovirus 3C protease inhibitors: Recent development. Exp Opin Ther Patents 1998, 8: 1151-6.
62. Wang, Q.M. Protease inhibitors as potential antiviral agents for the treatment of picornaviral infections. Prog Drug Res 1999, 52: 197-219.
63. Kaldor, S.W., Hammond, M., Dressman, B.A. et al. Glutamine-derived aldehydes for the inhibition of human rhinovirus 3C protease. Bioorg Med Chem Lett 1995, 5: 2021-6.
64. Shepherd, T.A., Cox, G.A., McKinney, E. et al. Small peptidic aldehyde inhibitors of human rhinovirus 3C protease. Bioorg Med Chem Lett 1996, 6: 2893-6.
65. Webber, S.E., Okano, K., Little, T.L. et al. Tripeptide aldehyde inhibitors of human rhinovirus 3C protease: Design, synthesis, biological evaluation, and cocrystal structure solution of P1 glutamine isosteric replacements. J Med Chem 1998, 41: 2786-805.
66. Hanzlik, R.P., Thompson, S.A. Vinylogous amino acid esters: A new class of inactivators for thiol proteases. J Med Chem 1984, 27: 711-2.
67. Liu, S., Hanzlik, R.P. Structure-activity relationships for inhibition of papain by peptide Michael acceptors. J Med Chem 1992, 35: 1067-75.
68. Kong, J.S., Venkatraman, S., Furness, K. et al. Synthesis and evaluation of peptidyl Michael acceptors that inactivate human rhinovirus 3C protease and inhibit virus replication. J Med Chem 1998, 41: 2579-87.
69. Dragovich, P.S., Webber, S.E., Babine, R.E. et al. Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 1. Michael acceptor structure-activity studies. J Med Chem 1998, 41: 2806-18.
70. Dragovich, P.S., Webber, S.E., Babine, R.E. et al. Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 2. Peptide structure-activity studies. J Med Chem 1998, 41: 2819-34.
71. Dragovich, P.S., Webber, S.E., Prins, T.J. et al. Structure-based design of irreversible, thpeptidyl human rhinovirus 3C protease inhibitors containing N-methyl amino acids. Bioorg Med Chem Lett 1999, 9: 2189-94.
72. Dragovich, P.S., Prins, T.J., Zhou, R. et al. Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 3. Structure-activity studies of ketomethylene-containing peptidomimetics. J Med Chem 1999, 42: 1203-12.
73. Dragovich, P.S., Prins, T.J., Zhou, R. et al. Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 4. Incorporation of P1 lactam moieties as L-glutamine replacements. J Med Chem 1999, 42: 1213-24.
74. Patick, A.K., Binford, S.L., Brothers, M.A. et al. In vitro antiviral activity of AG7088, a potent inhibitor of human rhinovirus 3C protease. Antimicrob Agents Chemother 1999, 43: 2444-50.
75. Matthews, D.A., Dragovich, P.S., Webber, S.E. et al. Structure-assisted design of mechanism-based irreversible inhibitors of human rhinovirus 3C protease with potent antiviral activity against multiple rhinovirus serotypes. Proc Natl Acad Sci USA 1999, 96: 11000-7.
76. Sham, H.L., Rosenbrook, W., Kati, W. et al. Potent inhibitor of the human rhinovirus (HRV) 3C protease containing a backbone modified glutamine. J Chem Soc Perkin Trans I 1995, 1081-2.
77. Kati, W.M., Sham, H.L, McCall, J.O. et al. Inhibition of 3C protease from human rhinovirus strain 1B by peptidyl bromomethylketonehydrazides. Arch Biochem Biophys 1999, 362: 363-75.
78. Venkatraman, S., Kong, J., NimKar, S., Wang, Q.M., Aube, J., Hanzlik, R.P. Design, synthesis, and evaluation of azapeptides as substrates and inhibitors for human rhinovirus 3C protease. Bioorg Med Chem Lett 1999, 9: 577-80.
79. Skiles, J.W., McNeil, D. Spiro indolinone beta-lactam inhibitors of poliovirus and rhinovirus 3C proteinases. Tetrahedron Lett 1990, 31: 7277-80.
80. Webber, S.E., Tikhe, J., Worland, S.T. et al. Design, synthesis, and evaluation of nonpeptidic inhibitors of human rhinovirus 3C protease. J Med Chem 1996, 39: 5072-82.
81. Jungheim, L.N., Cohen, J.D., Johnson, R.B. et al. Inhibition of human rhinovirus 3C protease by homophthalimides. Bioorg Med Chem Lett 1997, 7: 1589-94.
82. Singh, S.B., Cordingley, M.G., Ball, R.G., Smith, J.L., Dombrowski, A.W., Goetz, M.A. Structure and stereochemistry of thysanone: A novel human rhinovirus 3C protease inhibitor from Thysanopnora penicilloides. Tetrahedron Lett 1991, 32: 5279-82.
83. Kadam, S., Podding, J., Humphrey, P.E. et al. Citrinin hydrate and radicinin: Human rhinovirus 3C protease inhibitors discovered in a target-directed microbial screen. J Antibiotics 1994, 46: 836-9.
84. Brill, G.M., Kati, W.M., Montgomery, D. et al. Novel triterpene sulfates from Fusarium compactum using a rhinovirus 3C protease inhibitor screen. J Antibiotics 1996, 49: 541-6.
85. Wang, Q.M., Johnson, R.B., Jungheim, L.N., Cohen, J.D., Villarreal, E.C. Dual inhibition of human rhinovirus 2A and 3C proteases by homophthalimides. Antimicrob Agents Chemother 1998, 42: 916-20.
86. Korant, B.D., Towatari, T., Ivanoff, L. et al. Viral therapy: Prospects for protease inhibitors. J Cell Biochem 1996, 32: 91-5.